{
  "ticker": "NAMS",
  "company_name": "NewAmsterdam Pharma Company N.V",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT06048302",
      "title": "PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Hepatic Impairment, Healthy",
      "start_date": "2023-11-30",
      "completion_date": "2024-03-19",
      "enrollment": 0,
      "sponsor": "NewAmsterdam Pharma"
    },
    {
      "nct_id": "NCT04770389",
      "title": "Randomized Study of Obicetrapib in Combination With Ezetimibe",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Dyslipidemias, High Cholesterol, Hypercholesterolemia",
      "start_date": "2021-02-23",
      "completion_date": "2021-06-30",
      "enrollment": 0,
      "sponsor": "NewAmsterdam Pharma"
    },
    {
      "nct_id": "NCT06496243",
      "title": "Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Dyslipidemias",
      "start_date": "2024-12-02",
      "completion_date": "2026-02",
      "enrollment": 0,
      "sponsor": "NewAmsterdam Pharma"
    },
    {
      "nct_id": "NCT06250205",
      "title": "Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy Volunteers",
      "start_date": "2024-02-05",
      "completion_date": "2024-04-26",
      "enrollment": 0,
      "sponsor": "NewAmsterdam Pharma"
    },
    {
      "nct_id": "NCT05202509",
      "title": "Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "condition": "Atherosclerotic Cardiovascular Disease",
      "start_date": "2022-02-07",
      "completion_date": "2026-11",
      "enrollment": 0,
      "sponsor": "NewAmsterdam Pharma"
    },
    {
      "nct_id": "NCT05161715",
      "title": "Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Early Alzheimer's Disease",
      "start_date": "2022-01-12",
      "completion_date": "2023-06-01",
      "enrollment": 0,
      "sponsor": "NewAmsterdam Pharma"
    },
    {
      "nct_id": "NCT07219602",
      "title": "A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome",
      "status": "NOT_YET_RECRUITING",
      "phase": "PHASE3",
      "condition": "Lipidemia, Type 2 Diabetes (T2DM), Metabolic Syndrome (MetS)",
      "start_date": "2025-12",
      "completion_date": "2028-06",
      "enrollment": 0,
      "sponsor": "NewAmsterdam Pharma"
    },
    {
      "nct_id": "NCT05142722",
      "title": "Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Dyslipidemias, High Cholesterol, Hypercholesterolemia, Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease",
      "start_date": "2021-12-15",
      "completion_date": "2024-09-26",
      "enrollment": 0,
      "sponsor": "NewAmsterdam Pharma"
    },
    {
      "nct_id": "NCT06305559",
      "title": "A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "Lipidemia, Coronary Artery Disease, Plaque, Atherosclerotic",
      "start_date": "2024-05-16",
      "completion_date": "2027-03",
      "enrollment": 0,
      "sponsor": "NewAmsterdam Pharma"
    },
    {
      "nct_id": "NCT06982508",
      "title": "Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Antioxidant Absorption",
      "start_date": "2025-09-09",
      "completion_date": "2026-12",
      "enrollment": 0,
      "sponsor": "NewAmsterdam Pharma"
    }
  ],
  "summary": {
    "total_trials": 19,
    "by_phase": {
      "PHASE1": 6,
      "PHASE2": 7,
      "PHASE3": 6
    },
    "by_status": {
      "COMPLETED": 13,
      "RECRUITING": 3,
      "ACTIVE_NOT_RECRUITING": 2,
      "NOT_YET_RECRUITING": 1
    },
    "active_trials": 5,
    "completed_trials": 13,
    "conditions": [
      "Antioxidant Absorption",
      "Atherosclerotic Cardiovascular Disease",
      "Dyslipidemia, Hypercholesterolemia, High Cholesterol",
      "Dyslipidemias",
      "Dyslipidemias, High Cholesterol, Hypercholesterolemia",
      "Dyslipidemias, High Cholesterol, Hypercholesterolemia, Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease",
      "Dyslipidemias, High Cholesterol, Hypercholesterolemia, Familial Hypercholesterolemia, Lipid Metabolism Disorder, Metabolic Disease, Lipid Metabolism, Inborn Errors, Genetic Disease, Inborn, Hyperlipoproteinemias",
      "Dyslipidemias, Hypercholesterolemia, Familial Hypercholesterolemia, ASCVD, High Cholesterol",
      "Early Alzheimer's Disease",
      "Healthy Volunteer Study",
      "Healthy Volunteers",
      "Hepatic Impairment, Healthy",
      "Lipid Metabolism",
      "Lipidemia, Coronary Artery Disease, Plaque, Atherosclerotic",
      "Lipidemia, Type 2 Diabetes (T2DM), Metabolic Syndrome (MetS)"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:20:12.888798",
    "search_query": "NewAmsterdam Pharma Company N.V",
    "url": "https://clinicaltrials.gov/search?term=NewAmsterdam+Pharma+Company+N.V"
  }
}